Your browser doesn't support javascript.
loading
Botox (OnabotulinumtoxinA) for Treatment of Migraine Symptoms: A Systematic Review.
Shaterian, Negar; Shaterian, Negin; Ghanaatpisheh, Aref; Abbasi, Farnaz; Daniali, Sara; Jahromi, Maryam Jalali; Sanie, Mohammad Sadegh; Abdoli, Amir.
Afiliación
  • Shaterian N; Zoonoses Research Center, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Shaterian N; Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Ghanaatpisheh A; USERN Office, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Abbasi F; School of Nursing & Midwifery, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Daniali S; Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Jahromi MJ; USERN Office, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Sanie MS; Student Research Committee, Jahrom University of Medical Sciences, Jahrom, Iran.
  • Abdoli A; USERN Office, Jahrom University of Medical Sciences, Jahrom, Iran.
Pain Res Manag ; 2022: 3284446, 2022.
Article en En | MEDLINE | ID: mdl-35401888
Background: Migraine is one of the most common types of headache, and it is the second most common cause of neurological disorders, with an annual prevalence of about 15% of the population. This study aimed to evaluate the effect of BoNT-A on the duration and intensity of migraine attacks. In addition, we investigated the effective injection sites. Methods: According to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, we searched online databases, including Web of Science, PubMed, EMBASE, Scopus, Cochrane Library, ProQuest, ClinicalTrials.gov, and Google Scholar from 2011 to 2021. Results: A total of 24 articles were included in the study. The use of BoNT-A in individuals suffering from chronic migraine (CM) decreases the frequency of migraine attacks per month, pain intensity, medication use, emergency visits, and migraine-related disabilities. The BoNT-A was well tolerated and leads to improved performance and better quality of life (QoL). Overall, treatment with BoNT-A in adults with CM is beneficial. In addition, the use of BoNT-A in individuals with vestibular migraine (VM) reduces the frequency of migraines and brings about the improvement of disability status caused by migraine headaches. Meanwhile, the use of BoNT-A reduces the frequency of migraine attacks per month among individuals with chronic refractory migraine (CRM). Conclusions: The use of BoNT-A is a low-cost option for the treatment of various kinds of migraines, including chronic, episodic, unilateral, and vestibular types. BoNT-A can reduce the frequency of migraine attacks per month and diminish the severity of pain.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxinas Botulínicas Tipo A / Trastornos Migrañosos Tipo de estudio: Diagnostic_studies / Guideline / Risk_factors_studies / Systematic_reviews Aspecto: Patient_preference Límite: Adult / Humans Idioma: En Revista: Pain Res Manag Asunto de la revista: NEUROLOGIA / PSICOFISIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Toxinas Botulínicas Tipo A / Trastornos Migrañosos Tipo de estudio: Diagnostic_studies / Guideline / Risk_factors_studies / Systematic_reviews Aspecto: Patient_preference Límite: Adult / Humans Idioma: En Revista: Pain Res Manag Asunto de la revista: NEUROLOGIA / PSICOFISIOLOGIA Año: 2022 Tipo del documento: Article País de afiliación: Irán Pais de publicación: Estados Unidos